Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Alastair Greystoke

Newcastle AuthorsTitleYearFull text
Professor Ruth Plummer
Dr Alastair Greystoke
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours2019
Alice Coomer
Dr Fiona Black
Dr Alastair Greystoke
Dr Jennifer Munkley
Professor David Elliott
et al.
Alternative splicing in lung cancer2019
Dr Alastair Greystoke
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomalformulation in patients with solid tumours2019
Dr Maziar Navidi
Alexander Phillips
Professor Michael Griffin
Dr Alastair Greystoke
Dr Kate Sumpter
et al.
Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer2018
Dr Joanna Perthen
Dr Tamir Ali
David McCulloch
Maziar Navidi
Alexander Phillips
et al.
Intra- and Interobserver Variability in Skeletal Muscle Measurements using Computed Tomography Images2018
Dr Alastair Greystoke
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)2017
Dr Alastair Greystoke
Dr Noor MD Haris
Professor Ruth Plummer
SELECT-3: A phase i study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting2017
Dr David Jamieson
Melanie Griffin
Julieann Sludden
Dr Yvette Drew
Dr Nicola Cresti
et al.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours2016
Dr Nicola Wyatt
Dr Linda Hogarth
Dianne Turner
Dr Miranda Patterson
Dr David Jamieson
et al.
Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)2016
Dr Sally Hall
Dr Alastair Greystoke
Dr Christopher Jones
Dr Jane Margetts
Crizotinib in clinical practice: the North East of England's experience2016
123